From: Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons?
Trial name (reference) | Cell type | Source | Route of delivery | Endpoint | Phase of trial | Number of patients | Disease status | Study identifier | Trial title |
---|---|---|---|---|---|---|---|---|---|
MARVEL/Warren et al. | Skeletal myoblasts | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 170 | Ischemic cardiomyopathy | NCT00526253 | To Assess Safety and Efficacy of Myoblast Implantation Into Myocardium Post Myocardial Infarction |
MYSTAR-5-YEAR/Mariann et al. | BM mononuclear cells | Autologous | Intramyocardial and intracoronary | Safety/efficacy | Phase I and II | 60 | Ischemic cardiomyopathy | NCT01395212 | Long-term Follow-up of Patients With Ischemic Heart Disease Treated With Stem Cell Therapy |
COAT/Sandeep et al. | BM mononuclear cells | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 40 | Ischemic cardiomyopathy | NCT01625949 | Stem Cell Therapy in Patients With Myocardial Infarction and Persistent Total Occlusion of Infarct Related Artery |
AMIRST/Ashok et al. | BM mononuclear cells | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 30 | Acute MI | NCT01536106 | Rapid Delivery of Autologous Bone Marrow Derived Stem Cells in Acute Myocardial Infarction Patients |
BAMI/Anthony et al. | BM mononuclear cells | Autologous | Intracoronary | Safety/efficacy | Phase III | 3,000 | Acute MI | NCT01569178 | The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells (BM-MNC) on All Cause Mortality in Acute Myocardial Infarction |
AMR-1/Arshed et al. | BM CD34+ | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 40 | Acute MI | NCT00313339 | Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction |
PreSERVE-AMI/ Arshed et al. | BM CD34+ | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 160 | Ischemic cardiomyopathy | NCT01495364 | AMR-001 Versus Placebo Post ST Segment Elevation Myocardial Infarction |
NOGA-DCM/Vrtovec et al. | BM CD34+ | Autologous | Intramyocardial versus intracoronary | Safety/efficacy | Phase I and II | 90 | Dilated cardiomyopathy | NCT01350310 | Safety and Efficacy Study of Intramyocardial Stem Cell Therapy in Patients With Dilated Cardiomyopathy |
IMPACT-CABG/ Nicolas et al. | BM CD133+ | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 20 | Ischemic cardiomyopathy | NCT01033617 | IMPlantation of Autologous CD133+ sTem Cells in Patients Undergoing CABG |
PERFECT/Gustav et al. | BM CD133+ | Autologous | Intramyocardial | Efficacy | Phase II | 142 | Ischemic cardiomyopathy | NCT00950274 | Intramyocardial Transplantation of Bone Marrow Stem Cells in Addition to Coronary Artery Bypass Graft (CABG) Surgery |
SELECT-AMI/Jozef et al. | BM CD133+ | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 60 | Acute MI | NCT00529932 | A Trial Using CD133 Enriched Bone Marrow Cells Following Primary Angioplasty for Acute Myocardial Infarction |
AlsterMACS | BM CD133+ | Autologous | Intramyocardial versus intracoronary | Safety/efficacy | Phase I and II | 64 | Ischemic cardiomyopathy | NCT01337011 | Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells |
ENACT-AMI/ Duncan et al. | Endothelial progenitor cells | Autologous | Intracoronary | Efficacy | Phase II | 100 | Acute MI | NCT00936819 | Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial |
REPAIR-ACS/Andreas et al. | BM derived progenitor cells | Autologous | Intracoronary | Efficacy | Phase II | 100 | Acute MI | NCT00711542 | Effects of Intracoronary Progenitor Cell Therapy on Coronary Flow Reserve After Acute MI |
ESTIMATION/Evgeny et al. | BM MSCs | Autologous | Intramyocardial | Efficacy | Phase II | 50 | Acute MI | NCT01394432 | Study for Endocardial Mesenchymal Stem Cells Implantation in Patients After Acute Myocardial Infarction |
Kastrup et al. | BM MSCs | Autologous | Intramyocardial | Efficacy | Phase II | 60 | Ischemic cardiomyopathy | NCT00644410 | Autologous Mesenchymal Stromal Cell Therapy in Heart Failure |
Maskon et al. | BM MSCs | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 80 | Ischemic cardiomyopathy | NCT01720888 | Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy |
RELIEF/Yang et al. | BM MSCs | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 135 | Acute MI | NCT01652209 | A Randomized, Open labEled, muLticenter Trial for Safety and Efficacy of Intracoronary Adult Human Mesenchymal stEm Cells Acute Myocardial inFarction |
MESAMI/ Jerome et al. | BM MSCs | Autologous | Intramyocardial | Safety | Phase I | 10 | Ischemic cardiomyopathy | NCT01076920 | Mesenchymal Stem Cells and Myocardial Ischemia |
PoseidonDCM/Joshua et al. | BM MSCs | Allogeneic versus autologous | Intramyocardial | Safety/efficacy | Phase I and II | 36 | Dilated cardiomyopathy | NCT01392625 | PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy |
Perin et al. | Mesenchymal precursor cells | Allogeneic | Intramyocardial | Safety/efficacy | Phase I and II | 25 | Ischemic cardiomyopathy | NCT00555828 | Safety Study of Allogeneic Mesenchymal Precursor Cells (MPCs) in Subjects With Recent Acute Myocardial Infarction |
AMICI/ Eric et al. | Mesenchymal precursor cells | Allogeneic | Intracoronary | Safety/efficacy | Phase I and II | 225 | Acute MI | NCT01781390 | Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in MyoCardial Infarction |
MyStromalCell/Kastrup et al. | Adipose MSCs | Autologous | Intramyocardial | Efficacy | Phase II | 60 | Ischemic cardiomyopathy | NCT01449032 | MesenchYmal STROMAL CELL Therapy in Patients With Chronic Myocardial Ischemia |
ATHENA/Perin et al. | Adipose MSCs | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 45 | Ischemic cardiomyopathy | NCT01556022 | Safety and Feasibility Trial of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia |
PRECISE/Fernández-Avilés et al. | Adipose MSCs | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 36 | Ischemic cardiomyopathy | NCT00426868 | A Randomized Clinical Trial of adiPose-deRived stEm and Regenerative Cells In the Treatment of Patients With Non revaScularizable ischEmic Myocardium |
APOLLO/Serruys et al. | Adipose MSCs | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 48 | Acute MI | NCT00442806 | A Randomized Clinical Trial of AdiPOse-derived Stem ceLLs in the Treatment of Patients With ST-elevation myOcardial Infarction |
RIMECARD | Umbilical cord MSCs | Allogeneic | Intravenous | Safety/efficacy | Phase I and II | 30 | Ischemic cardiomyopathy | NCT01739777 | Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy |
CHART-1/Terzic et al. | BM MSC cardiopoietic cells | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 240 | Ischemic cardiomyopathy | NCT01768702 | Safety and Efficacy of Autologous Cardiopoietic Cells for Treatment of Ischemic Heart Failure |
RECONSTRUCT/Marban et al. | Cardiosphere-derived cells | Autologous | Intramyocardial | Safety/efficacy | Phase I and II | 24 | Ischemic cardiomyopathy | NCT01496209 | REgenerative CardiOsphere iNjection to STRengthen dysfUnCTional Hearts |
ALLSTAR/Smith et al. | Cardiosphere-derived cells | Allogeneic | Intracoronary | Safety/efficacy | Phase I and II | 274 | Ischemic cardiomyopathy | NCT01458405 | Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration |
Gourabi et al. | Cardiac stem cells | Autologous | Intracoronary | Safety/efficacy | Phase I and II | 50 | Ischemic cardiomyopathy | NCT01758406 | Transplantation of Autologous Cardiac Stem Cells in Ischemic Heart Failure |
MESS/Mariann et al. | Cardiac stem cells | Autologous | Intracoronary | Safety/efficacy | Phase III | 1,000 | Ischemic cardiomyopathy | NCT01098591 | Meta-analysis of Cardiac Stem Cell Studies |